Helsinn Healthcare SA
https://www.helsinn.com/public/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Helsinn Healthcare SA
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid
Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.
Stake Sale Speculation At Two PE-Controlled Firms In India: Will Valuations Fly?
Two top-50 Indian firms are speculated to be on the block with valuations expected to be richer than past multiples paid by buyers. A small, less known life sciences solutions provider is also keen to rope in a CDMO partner. Scrip speaks to a cross-section of experts on the action in deal street.
Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual
In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.
Company Information
- Industry
- Distributors
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Sapphire Therapeutics
- Helsinn Pharmaceuticals Beijing Co. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice